Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Core Insights - Phio Pharmaceuticals has appointed Mr. David H. Deming as Lead Independent Director, bringing over 30 years of experience in investment banking and asset management to the role [1][2][3] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology aimed at eliminating cancer [1][4] - The company's lead clinical program is PH-762, which targets the PD-1 gene associated with various skin cancers and is currently undergoing a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] Leadership Experience - Mr. Deming has a significant background in investment banking, having spent over 27 years at JP Morgan, where he led the Health Group in investment banking for the last 12 years of his tenure [2] - His experience in the biopharma sector and corporate boards is expected to provide valuable insights as Phio advances its gene silencing technology [3]